Key Figures Q4 2023

SEK m, unless otherwise stated

2023
Oct-Dec

2022
Oct-Dec

2023
Jan-Dec

2022
Jan-Dec

% Change

 
Net revenues 166.0 156.1 638.8 624.3 2.3%  
Cost of goods sold -20.1 -25.9 -88.9 -102.6 -13.4%  
Operating expenses -154.5 -201.3 -659.5 -705.6 -6.5%  
EBIT -8.6 -71.1 -109.5 -183.9 40.5%  
EBIT margin, % -5.2% -45.6% -17.1% -29.5% 42.0%  
EBITDA 12.4 -53.1 -32.5 -115.2 71.8%  
Earnings per share, before dilution, SEK -0.54 -2.67 -3.73 -5.17 27.8%  
Earnings per share, after dilution, SEK -0.54 -2.67 -3.73 -5.17 27.8%  
Cash flow from operating activities -2.6 -48.9 -95.0 -156.6 39.3%  
Cash and invested funds 171.0 351.9 171.0 351.9 -51.4%  


Net revenues and EBIT per segment Q4 2023

 

Net Revenues

EBIT


SEK m

2023
Oct-Dec

2022
Oct-Dec

2023
Jan-Dec

2022
Jan-Dec

2023
Oct-Dec

2022
Oct-Dec

2023
Jan-Dec

2022
Jan-Dec

ZUBSOLV® US 151.3 142.6 577.7 571.4 - - - -
US Pharma – total 151.3 142.6 577.7 571.4 75.4 77.0 283.1 308.4
Digital Therapeutics (DTx) product sales 0.0 0.0 0.0 0.4 - - - -
Digital Therapeutics (DTx) – total 0.0 0.0 0.0 0.4 -29.1 -49.0 -130.9 -189.1
Abstral® royalties 10.0 5.5 31.9 30.4 - - - -
Edluar® royalties 1.9 2.7 10.8 10.4 - - - -
ZUBSOLV® - ex US 2.8 5.2 18.4 11.8 - - - -
HQ & Pipeline - total 14.7 13.4 61.1 52.6 -54.9 -99.1 -261.8 -303.2
Total 166.0 156.1 638.8 624.3 -8.6 -71.1 -109.5 -183.9


Cash flow Q4 2023


SEK m

2023
Oct-Dec

2022
Oct-Dec

2023
Jan-Dec

2022
Jan-Dec

 
Cash flow from operating activities -2.6 -48.9 -95.0 -156.6  
Investment activities -0.9 66.2 200.8 -234.7  
Financing activities -5.6 -5.8 -70.1 -21.4  
Cash flow (excl exchange rate differences) -9.1 11.5 35.7 -412.8  
Cash and cash equivalents 171.0 132.2 171.0 132.2